Terms: = Endocrine gland cancer AND TSC1, KIAA0243, 7248, ENSG00000165699, TSC, MGC86987, LAM, hamartin AND Prognosis
13 results:
1. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer.
Lu SY; Hua J; Liu J; Wei MY; Liang C; Meng QC; Zhang B; Yu XJ; Wang W; Xu J
BMC Med Genomics; 2022 Oct; 15(1):218. PubMed ID: 36261830
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
[TBL] [Abstract] [Full Text] [Related]
3. Phakomatoses and endocrine gland Tumors: Noteworthy and (Not so) Rare Associations.
Chevalier B; Dupuis H; Jannin A; Lemaitre M; Do Cao C; Cardot-Bauters C; Espiard S; Vantyghem MC
Front Endocrinol (Lausanne); 2021; 12():678869. PubMed ID: 34025587
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract] [Full Text] [Related]
5. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract] [Full Text] [Related]
6. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract] [Full Text] [Related]
7. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract] [Full Text] [Related]
8. miR-130a upregulates mTOR pathway by targeting tsc1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma.
Wang Y; Zhang X; Tang W; Lin Z; Xu L; Dong R; Li Y; Li J; Zhang Z; Li X; Zhao L; Wei JJ; Shao C; Kong B; Liu Z
Cell Death Differ; 2017 Dec; 24(12):2089-2100. PubMed ID: 28800130
[TBL] [Abstract] [Full Text] [Related]
9. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
[TBL] [Abstract] [Full Text] [Related]
10. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
[TBL] [Abstract] [Full Text] [Related]
11. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer.
Tanwar PS; Mohapatra G; Chiang S; Engler DA; Zhang L; Kaneko-Tarui T; Ohguchi Y; Birrer MJ; Teixeira JM
Carcinogenesis; 2014 Mar; 35(3):546-53. PubMed ID: 24170201
[TBL] [Abstract] [Full Text] [Related]
12. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
[TBL] [Abstract] [Full Text] [Related]
13. Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells.
Wani AA; Sharma N; Shouche YS; Bapat SA
Oncogene; 2006 Oct; 25(47):6336-44. PubMed ID: 16732329
[TBL] [Abstract] [Full Text] [Related]
